Follow FrankTwisk on Twitter  





Invest in ME

kondigt "eerste fase"

van de Rituximab-trial aan 










Dankzij de gift van een liefdadigheidsinstelling, die anoniem wil blijven,

kan de "eerste" fase van de Rituximab-trial in Engeland van start gaan.


Eigenlijk is er nog niet echt sprake van een Rituximab-trial,

want de eerste fase betreft het onderzoeken van B-cel populaties n.a.v. een studie van Bansal et al.


Wordt vervolgd.





Invest in ME Statement

The UK Rituximab Trial for ME


August 2013


On 6th June nvest in ME announced that we were in discussions

to set up a UK trial of rituximab for ME patients and

since that announcement things have been progressing well.


The charity had been working on trying to get such a trial started

since the IIMEC7 conference- click here.


In updates published through June/July,

we have stated that all that is required for the trial to proceed is the funding.


As such, IiME began fundraising for this trial and invited everyone to support us in this project.


Recently we arranged a specific web site

which has been set up to inform on all aspects of the UK rituximab trial.

This is at -

and we reiterated the current status - (click here)

  • We have the facilities available.
  • We have the researchers available.
  • We have the best expertise possible available.
  • We have the means of fundraising for this trial available (see The MATRIX - click here)
  • and we have a campaign to raise funds

As we have agreed with our advisor, Professor Jonathan Edwards,

the proposed clinical trial will undergo a rigorous peer review process.


We have reached this position thanks to the vision, efforts and help

from Professor Edwards, Dr Cambridge, UCL and our supporters.


We have emphasised from when we announced the trial

that the only element required is funding.


IiME will continue organising and raising funds for this trial.


The IiME BRF Rituximab fund is specifically ring-fenced in a separate account for the UK rituximab trial.


The first part of the trial will be a preliminary study

which will be designed to confirm and extend the earlier work of

Dr Amolak Bansal [1] on B-cells but using a different cohort of ME patients.


Professor Edwards believes this is a useful study in its own right and

a pre-requisite for the clinical trial.


Meanwhile work is continuing on the design of a protocol

which will be finalised after the trip to Bergen that IiME and Professor Edwards have arranged.


Good progress is being made and IiME are committed to expedite this trial as best we can.


To achieve this IiME has recently been in discussions with a charitable foundation

with a view to help in funding this work.


We are enormously pleased to announce that,

thanks to the extraordinary generosity and support of the foundation's representative,

our biomedical research fund for the UK rituximab trial has now reached 50,000.


This is due to a donation from the charitable foundation

which will match our existing BRF rituximab total of 25,000 - click here.


The charitable foundation currently wishes to remain anonymous

but they have asked us to keep them informed of the progress of plans for the trial and

we are sure that the ME community will join us in thanking them for this wonderful support.


This now means that the first part of this project can be initiated by the UCL team without delay.


We thank all those who are supporting this trial and

we will continue to provide information on the status of the trial as we progress.


We now resolve to increase our efforts to raise the remaining funds for the trial and

ask for your continued support in this project in the knowledge

that it will benefit all people with ME and their families.


The fundraising for this trial is being organised and coordinated by IiME

so please contact IiME directly if you or your organisation would like to assist or contribute.


If anyone would like to ask any questions about the UK rituximab trial

then please use the Contact form on the rituximab web site (click here).


In summary we feel that the best research team possible to undertake this trial

is now able to begin the work - taking a huge leap forward in ME research in the UK.


Thank You.




  1. Bradley, A. S., Ford, B. and Bansal, A. S. (2013),
  2. Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls.

    Clinical & Experimental Immunology, 172: 7380. doi: 10.1111/cei.12043.